BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company leverages its proprietary NAi Interrogative Biology Platform, protected by over 500 patents, and a large clinically annotated biobank with access to a supercomputer to model patient biology and develop therapeutics. With a pipeline spanning oncology, rare diseases, and neurology, BPGbio aims to transform medicine through biology, multi-modal data, and AI.
Industries
Nr. of Employees
medium (51-250)
Patents
Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US-12209285-B2
View DetailsInterrogatory cell-based assays for identifying drug-induced toxicity markers
US-11694765-B2
View Details
Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
US-12209285-B2
View DetailsInterrogatory cell-based assays for identifying drug-induced toxicity markers
US-11694765-B2
View DetailsProducts
BPM31510
Investigational lipid-conjugated CoQ10 formulation developed as an intravenous lipid nanodispersion aimed at restoring CoQ10 levels, modulating mitochondrial oxidative phosphorylation, and reprogramming tumor metabolism; being evaluated in oncology and rare mitochondrial disease indications.
BRG399
Experimental oral microtubule-binding anti-mitotic agent under development with reported induction of immunogenic cell death and potential for combination immunotherapy across solid and liquid tumors.
BPM31510
Investigational lipid-conjugated CoQ10 formulation developed as an intravenous lipid nanodispersion aimed at restoring CoQ10 levels, modulating mitochondrial oxidative phosphorylation, and reprogramming tumor metabolism; being evaluated in oncology and rare mitochondrial disease indications.
BRG399
Experimental oral microtubule-binding anti-mitotic agent under development with reported induction of immunogenic cell death and potential for combination immunotherapy across solid and liquid tumors.
Services
Provision of causal/Bayesian AI analysis applied to multi-omic and clinical datasets to support target discovery, biomarker identification, and trial design.
Generation of spatially resolved molecular maps and mass-spectrometry-based quantitation to characterize drug distribution, tissue pharmacodynamics, and mechanism of action.
Discovery and optimization support for E2-targeted degradation modalities, including fragment screening, computational design, and selectivity assays.
Longitudinal multi-site biomarker studies and development of multi-protein diagnostic panels for early detection and patient stratification.
Out-licensing and strategic partnerships for late-stage therapeutic candidates and platform technologies.
Provision of causal/Bayesian AI analysis applied to multi-omic and clinical datasets to support target discovery, biomarker identification, and trial design.
Generation of spatially resolved molecular maps and mass-spectrometry-based quantitation to characterize drug distribution, tissue pharmacodynamics, and mechanism of action.
Discovery and optimization support for E2-targeted degradation modalities, including fragment screening, computational design, and selectivity assays.
Longitudinal multi-site biomarker studies and development of multi-protein diagnostic panels for early detection and patient stratification.
Out-licensing and strategic partnerships for late-stage therapeutic candidates and platform technologies.
Expertise Areas
- Causal AI-driven drug discovery
- Multi-omics and spatial omics
- Lipidomics and quinone metabolite analysis
- Targeted protein degradation (E2-focused)
Key Technologies
- Bayesian causal AI modeling
- Multi-omics (lipidomics, proteomics, metabolomics)
- Spatial omics (MALDI-MSI, spatial metabolomics)
- Mass spectrometry (LC-MS/MS, MALDI)
News & Updates
BPGbio will co-present studies on BPM31510 and BRG399, highlighting their potential in glioblastoma treatment, at the Society for Neuro-Oncology 2024 Annual Meeting.
BPGbio presented novel insights into BPM31510's pharmacodynamics and tissue distribution, demonstrating its ability to deliver CoQ10 to critical tissues and restore levels in a mouse model of primary CoQ10 deficiency.
BPGbio presented findings from Project Survival®, a 7-year clinical trial, revealing distinct metabolic subtypes of pancreatic ductal adenocarcinoma tied to patient survival, using multiomics analysis of plasma samples.
BPGbio to Present Advances in Spatial Omics Technology and Targeted Protein Degradation at ASMS 2025
BPGbio announced its participation in the ASMS 2025 conference, showcasing research in spatial omics and mass spectrometry-enabled proteomics related to its therapeutic programs.
BPGbio was recognized in GEN's list of ten companies making progress in AI drug discovery, with CEO Niven R. Narain highlighted for his work at the intersection of biology, AI, and translational medicine.
Niven R. Narain discusses how AI accelerates drug discovery but emphasizes the importance of understanding patient biology for true innovation.
BPGbio will co-present studies on BPM31510 and BRG399, highlighting their potential in glioblastoma treatment, at the Society for Neuro-Oncology 2024 Annual Meeting.
BPGbio presented novel insights into BPM31510's pharmacodynamics and tissue distribution, demonstrating its ability to deliver CoQ10 to critical tissues and restore levels in a mouse model of primary CoQ10 deficiency.
BPGbio presented findings from Project Survival®, a 7-year clinical trial, revealing distinct metabolic subtypes of pancreatic ductal adenocarcinoma tied to patient survival, using multiomics analysis of plasma samples.
BPGbio to Present Advances in Spatial Omics Technology and Targeted Protein Degradation at ASMS 2025
BPGbio announced its participation in the ASMS 2025 conference, showcasing research in spatial omics and mass spectrometry-enabled proteomics related to its therapeutic programs.
BPGbio was recognized in GEN's list of ten companies making progress in AI drug discovery, with CEO Niven R. Narain highlighted for his work at the intersection of biology, AI, and translational medicine.
Niven R. Narain discusses how AI accelerates drug discovery but emphasizes the importance of understanding patient biology for true innovation.